Table 3.
Characteristic | Number | Percentage |
---|---|---|
Age >60 years | 15/31 | 48.4% |
Male sex | 22/31 | 71.0% |
Region | ||
Europe | 15/31 | 48.4% |
America | 8/31 | 25.8% |
Asia | 8/31 | 25.8% |
Concurrent tumors | 21/26 | 80.8% |
Blood only | 5/26 | 19.2% |
B symptoms | 6/15 | 40.0% |
FLIPI | ||
Low (0–2 points) | 8/17 | 47.1% |
High (3–5 points) | 9/17 | 52.9% |
WBC count >100/uL | 8/27 | 29.6% |
CD10 expression | 27/29 | 93.1% |
CD20 expression | 31/31 | 100% |
BCL2/IgH gene rearrangement* | 19/22 | 86.4% |
Therapy | ||
R-chemotherapy | 17/24 | 70.8% |
Chemotherapy | 6/24 | 25.0% |
None | 1/24 | 4.2 |
Outcome | ||
Alive | 22/26 | 84.6% |
Dead | 4/26 | 15.4% |
FLIPI: follicular lymphoma international prognostic index; WBC: white blood cell; IgH: immuhoglobulin heavy chain
By FISH or PCR